A M Issa

Summary

Affiliation: University of Houston
Country: USA

Publications

  1. ncbi request reprint Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges
    Amalia M Issa
    UCLA School of Public Health, Room 31 245A CHS, Campus Box 951772, Los Angeles, CA 90095 1772, USA
    Pharmacogenomics 4:647-55. 2003
  2. ncbi request reprint Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends
    Amalia M Issa
    Program in Personalized Medicine and Targeted Therapeutics, University of Houston, 300 Technology Building, Houston, TX 77204 4021, USA
    Curr Drug Saf 2:177-85. 2007
  3. doi request reprint Assessing patient readiness for the clinical adoption of personalized medicine
    A M Issa
    Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, The Methodist Hospital Research Institute, University of Houston, Houston, Texas 77204 4021, USA
    Public Health Genomics 12:163-9. 2009
  4. doi request reprint Clinical applications of pharmacogenomics to adverse drug reactions
    Amalia M Issa
    Program in Personalized Medicine and Targeted Therapeutics, The University of Houston, 300 Technology Building, Houston, TX 77204, USA
    Expert Rev Clin Pharmacol 1:251-60. 2008
  5. ncbi request reprint The regulation of pharmacogenomics-based drugs and policy making
    Amalia M Issa
    UCLA School of Public Health, CHS Room 31 245A, Box 951772, Los Angeles, CA 90095 1772, USA
    Curr Top Med Chem 4:1455-60. 2004
  6. ncbi request reprint Diagnostics and biomarker development: priming the pipeline
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA
    Nat Rev Drug Discov 5:463-9. 2006

Detail Information

Publications6

  1. ncbi request reprint Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges
    Amalia M Issa
    UCLA School of Public Health, Room 31 245A CHS, Campus Box 951772, Los Angeles, CA 90095 1772, USA
    Pharmacogenomics 4:647-55. 2003
    ..A critical analysis of some of the methodological design and ethical issues generated by the potential incorporation of pharmacogenomic profiling into pharmacosurveillance programs is presented...
  2. ncbi request reprint Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends
    Amalia M Issa
    Program in Personalized Medicine and Targeted Therapeutics, University of Houston, 300 Technology Building, Houston, TX 77204 4021, USA
    Curr Drug Saf 2:177-85. 2007
    ..A comprehensive approach will be needed to address the improvement of drug safety. We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts...
  3. doi request reprint Assessing patient readiness for the clinical adoption of personalized medicine
    A M Issa
    Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, The Methodist Hospital Research Institute, University of Houston, Houston, Texas 77204 4021, USA
    Public Health Genomics 12:163-9. 2009
    ....
  4. doi request reprint Clinical applications of pharmacogenomics to adverse drug reactions
    Amalia M Issa
    Program in Personalized Medicine and Targeted Therapeutics, The University of Houston, 300 Technology Building, Houston, TX 77204, USA
    Expert Rev Clin Pharmacol 1:251-60. 2008
    ..This paper focuses on the problem of adverse drug reactions and reviews the evidence and the state of the science for the application of pharmacogenomics to adverse drug reactions. ..
  5. ncbi request reprint The regulation of pharmacogenomics-based drugs and policy making
    Amalia M Issa
    UCLA School of Public Health, CHS Room 31 245A, Box 951772, Los Angeles, CA 90095 1772, USA
    Curr Top Med Chem 4:1455-60. 2004
    ..Hypothetical vignettes are used to illustrate a number of issues that are challenging to policy makers and the potential impact of pharmacogenomic based drug research and development on the regulatory environment...
  6. ncbi request reprint Diagnostics and biomarker development: priming the pipeline
    Kathryn A Phillips
    School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA
    Nat Rev Drug Discov 5:463-9. 2006
    ..Here, we characterize the pipeline problem for biomarkers and diagnostics, and consider what steps could be taken to solve it...